

IDERA PHARMACEUTICALS, INC.

Form 8-K

September 15, 2005

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): **September 12, 2005**  
**IDERA PHARMACEUTICALS, INC.**  
(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
(State or Other Juris-  
diction of Incorporation)

**001-31918**  
(Commission  
File Number)

**04-3072298**  
(IRS Employer  
Identification No.)

**345 Vassar Street,  
Cambridge, Massachusetts**  
(Address of Principal Executive Offices)

**02139**  
(Zip Code)

**(617) 679-5500**

Registrant's telephone number, including area code:  
**n/a**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 5.03: Amendments to Articles of Incorporation or Bylaws

Item 9.01: Financial Statements and Exhibits

SIGNATURE

EXHIBIT INDEX

EX-3.1 Certificate of Ownership and Merger

---

**Table of Contents**

**Item 5.03: Amendments to Articles of Incorporation or Bylaws**

Effective September 12, 2005, Hybridon, Inc. changed its name to Idera Pharmaceuticals, Inc. The Registrant began trading under a new American Stock Exchange symbol **IDP** on September 13, 2005. A copy of the Certificate of Ownership and Merger pursuant to which the name change was effectuated is attached as Exhibit 3.1 to this Current Report on Form 8-K.

**Item 9.01: Financial Statements and Exhibits**

(c) Exhibits

3.1 Certificate of Ownership and Merger merging Idera Pharmaceuticals, Inc., a wholly owned subsidiary of Hybridon, Inc., into Hybridon, Inc., effective September 12, 2005.

---

**Table of Contents**

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HYBRIDON, INC.

Date: September 14, 2005

By: /s/ Robert G. Andersen

Robert G. Andersen  
Chief Financial Officer and  
Vice President of Operations

---

**Table of Contents**

EXHIBIT INDEX

Exhibit No.	Description
3.1	Certificate of Ownership and Merger merging Idera Pharmaceuticals, Inc., a wholly owned subsidiary of Hybridon, Inc., into Hybridon, Inc., effective September 12, 2005.